| Name | Title | Contact Details |
|---|---|---|
Narinder Singh |
Executive Vice President of Technical Operations | Profile |
Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases.
Proclara is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by Alzheimer`s, Parkinson`s, and other diseases caused by protein misfolding. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
BreakBio Corp is a biotechnology company focused on breakthrough cancer treatment and prevention. They use their proprietary AI platform to find multiple proteins on each patients cancer cells and custom manufacture drugs for each patient. Their goal ...
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
Metabiota is the pioneer in comprehensive risk analytics that improve the world`s resilience to epidemics. Built on a strong foundation of epidemiology and international field science, including a worldwide network of on-the-ground experts, Metabiota delivers actionable, data-driven insights that help countries, governments and corporations manage and mitigate infectious diseases. With a strategic global presence and sustained partnerships, Metabiota`s agile approach is helping the world track and transfer the risk associated with epidemic threats.